NCT06855368 Biomarkers for Monitoring Dementia Progression
| NCT ID | NCT06855368 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele Roma |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-05-18 |
| Primary Completion | 2025-05-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-05-18 with a primary completion date of 2025-05-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention. Studying the etiopathogenesis and pathophysiological mechanisms of AD is a necessary prerequisite for the development of new biomarkers and innovative therapies. Contrarily to anatomical structures, cortical connectivity networks are already deteriorated in early AD and could be a reliable marker of early cognitive decline. Our aim is to characterize the neurophysiological parameters in mild AD, in patients with mild cognitive impairment and in matched healthy subjects to identify discriminating criteria. Concurrently, the study of AD onset and progression in a mouse model, will allow evaluating the causal effect of inflammation on disease progression and to develop a new class of biomimetic anti-inflammatory nanoparticles formulated to have the intrinsic ability to induce brain's activated microglia to an M2 phenotype.
Eligibility Criteria
Inclusion Criteria: * mild AD and patients with mild cognitive impairment (MCI). Exclusion Criteria: * major psychosis, genetic, metabolic and other neurological disorders, acute or chronic non-compensated medical illness * any medical or drug-related condition affecting cognitive or mood status * history or current alcohol/illicit drug abuse.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06855368 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06855368 currently recruiting?
Yes, NCT06855368 is actively recruiting participants. Contact the research team at lucia.gatta@sanraffaele.it for enrollment information.
Where is the NCT06855368 trial being conducted?
This trial is being conducted at Roma, Italy, Sassari, Italy.
Who is sponsoring the NCT06855368 clinical trial?
NCT06855368 is sponsored by IRCCS San Raffaele Roma. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.